Every health system I talk to can tell me what its CDI program captured last year. Far fewer can tell me how much of that revenue was ultimately realized and retained. The systems that measure these outcomes often do not talk to each other, and the teams responsible for them may not report to the same leader. The gap between revenue captured at billing and revenue ultimately retained is where a meaningful portion of hospital margin can disappear.
Documentation is incredibly important. Coding to the full clinical severity of what actually occurred during an encounter is real work. CDI platforms, coding technology, and acuity-capture tools can help providers perform that work accurately and consistently.
The way hospitals measure financial value is incomplete.
Revenue captured at billing is not the same as net revenue expected under the contract. Expected revenue is not necessarily the same as the payer’s initial payment. And an initial payment is not always the amount the health system ultimately keeps.
Payers can challenge reimbursement before or after payment. A pre-payment clinical validation or coding denial may reduce the DRG before the claim is paid. A post-payment audit may seek to recoup revenue months or even years later. Other reviews may result in a severity-of-illness reclassification, a retrospective inpatient-to-observation determination, or another reimbursement adjustment without producing what would traditionally be called a DRG downgrade.
These payer actions expose a measurement problem, revenue that appears fully captured at billing but fails to become durable, realized revenue.
The initial payment may be reported in one quarter by one team. A later takeback may appear in another period, under another team, buried within adjustments or write-offs. Without a measurement framework that connects those events to the original encounter, both numbers can be reported accurately, yet the hospital still lacks an accurate picture of financial performance. A revenue strategy evaluated only at billing or initial payment will look better than its ultimate economic result.
For many CDI vendors, gross capture is the central value story. Their attributed value often ends when the claim is coded, billed, or initially paid. What happens when the payer later disputes that reimbursement may fall outside the product, the measurement period, or the vendor’s contractual responsibility. That creates an incentive to report the largest defensible capture number before the entire revenue cycle has played out.
I have said before that much of the revenue cycle industry is built to make denials manageable rather than solve them. Incomplete measurement can reinforce the same structure. If one system measures documentation improvement, another manages denials, and another tracks payment adjustments, no one is necessarily responsible for determining whether the revenue was ultimately retained.
Additionally…
Payers do not make decisions based solely on whether documentation and coding are clinically defensible.
Payer adjudication and audit behavior may reflect plan-specific policies, contractual interpretations, clinical criteria, coding rules, geography, and changing review priorities. Accurate documentation remains essential, but accuracy alone does not guarantee payment durability. Providers must also understand where and why payers challenge otherwise supportable reimbursement.
The question revenue cycle leaders need to ask is not simply, “How much did we capture?” It’s, Of the revenue we captured, how much did we expect to collect, how much was initially paid, how much did we ultimately retain, and what did it cost us to defend the rest?
That means measuring performance across the full reimbursement lifecycle:
- Revenue captured at billing
- Contractually expected reimbursement
- Initial payer adjudication and payment
- Pre-payment denials and reclassifications
- Post-payment audits, recoupments, and takebacks
- Appeal outcomes and associated recovery costs
- Net revenue ultimately realized and retained
The economics of preventing an adverse payment outcome are structurally better than fighting it after it occurs. When a preventable denial, downgrade, or reclassification is avoided, there may be no appeal to staff, no physician pulled into a peer-to-peer review, no claim sitting unresolved in accounts receivable, and no balance written off because the cost of pursuing it exceeds the likely recovery. Remediation, however effective, still requires spending money to recover revenue the provider believes it already earned.
Revenue cycle leaders should understand net realized revenue per discharge and by payer after downstream adjustments, recoupments, and the cost of defending challenged reimbursement. Gross capture, case mix index, and denial rate each tell part of the story. None tells the whole story on its own.
If you cannot connect what was billed, what was expected, what was paid, what was challenged, and what was ultimately retained, you have a measurement problem (which may also be a revenue problem). That is worth fixing before investing another dollar in optimizing a number that stops halfway through the story.
Sift’s RevProtect Payments Intelligence Platform enables revenue cycle leaders to track, manage and prevent all forms of adverse payment outcomes.
